Have an account?
Log in to check out faster.
Loading...
May, 2024
June, 2024
Learn why you should start your probiotics journey with Bio-K+
Our scientifically proven formulas are designed to support your unique health journey
Probiotics for gum disease are an area of growing clinical research. This page reviews the science on probiotics and gum health, the strains studied in periodontal contexts, and what current evidence shows about probiotics for teeth and gum disease.
Gum disease develops when oral microbial balance shifts, allowing pathogens including Porphyromonas gingivalis, Treponema denticola, and Fusobacterium nucleatum to proliferate in the subgingival environment. This dysbiosis model is the rationale for studying probiotics for gum health: interventions that may support commensal populations or reduce pathogen proliferation are scientifically plausible. Evidence from clinical research is promising but constrained by study design limitations discussed throughout this page.
Periodontal probiotic research uses randomized controlled trials testing a probiotic as an adjunct to standard treatment, most commonly scaling and root planing. Clinical outcomes include probing depth, plaque index, and gingival bleeding; microbiological outcomes include subgingival pathogen counts. Study follow-up typically ranges from four to twelve weeks. Jayaram et al. (PMC, 2016, cited 90) noted that most studies report limited and transient improvements in periodontal parameters.
The most studied strain in periodontal probiotic research is Lactobacillus reuteri DSM 17938 and ATCC PTA 5289, combined as BioGaia Prodentis®. Multiple trials reported statistically significant reductions in gingival bleeding, plaque index, and subgingival Porphyromonas gingivalis counts. L. reuteri DSM 17938 has been observed to modulate prostaglandin E2 and interleukin-8 in gingival tissue. Evidence for these strain codes does not transfer to other L. reuteri strains without independent clinical validation.
Lactobacillus acidophilus strains have demonstrated reduced cariogenic bacteria in laboratory and limited clinical settings; strain designation determines evidence strength. Lactobacillus brevis CD2 produces arginine deiminase, potentially moderating gingival inflammation through a distinct mechanism. Streptococcus salivarius M18 produces dextranase, studied for disrupting plaque biofilm matrix; BLIS K12 produces bacteriocins studied for broader oral microbiome effects. Chugh et al. (2020) emphasized strain specificity prevents generalization across species.
Probiotic strains may affect gingival tissue through three mechanisms: competitive exclusion, direct antimicrobial activity, and immune modulation. Competitive exclusion occurs when probiotic bacteria occupy oral adhesion sites, reducing space for pathogens. Direct antimicrobial activity involves bacteriocin production and lactic acid generation unfavourable to specific pathogens. Immune modulation — reductions in pro-inflammatory cytokines in gingival crevicular fluid — has been observed in L. reuteri DSM 17938 and ATCC PTA 5289 trials.
Inchingolo et al. (2023) concluded probiotics may reduce cariogenic pathogens and have a role in periodontal health, noting optimal strain and dose remain unestablished. Doucette et al. (2024) confirmed reductions in pathogenic bacteria, with L. reuteri showing the strongest evidence. Van Holm et al. (2023) noted strain standardization limitations and inadequate long-term data. Most trials involve 20 to 60 subjects per arm with four to twelve week follow-up, insufficient for long-term outcomes.
All clinical evidence for probiotics in periodontal health was obtained as adjunct to professional care, not as a standalone alternative. Professional care — dental hygiene visits, scaling and root planing, and daily brushing and flossing — remains the foundation of gum health management. Probiotics for teeth and gums are not a replacement for dental treatment. Long-term validation is ongoing. Bio-K+ makes no gum or oral health claims.
Published research suggests certain strains — most notably Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 — may reduce gingival bleeding, plaque index scores, and subgingival pathogen counts when used as an adjunct to professional dental cleaning. Systematic reviews describe the evidence as promising but limited by small study sizes, short follow-up periods, and inconsistent strain selection. Probiotics have not been shown to reverse periodontal tissue damage, and they do not replace professional dental care. Consult a dentist for management of active gum disease.
The most clinically studied strains in periodontal contexts are Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 (combined as BioGaia Prodentis®), Lactobacillus brevis CD2 (studied for anti-inflammatory effects on gingival tissue), Streptococcus salivarius M18 (studied for plaque-associated bacteria), and various Lactobacillus acidophilus strains in laboratory and limited clinical settings. Evidence quality varies significantly by strain — L. reuteri DSM 17938 and ATCC PTA 5289 has the most consistent clinical trial base.
Three mechanisms are under investigation. Competitive exclusion: probiotic bacteria compete with periodontal pathogens for gingival adhesion sites. Direct antimicrobial activity: certain strains produce bacteriocins or generate lactic acid environments unfavourable to specific pathogens. Immune modulation: certain strains — particularly L. reuteri DSM 17938 — have been associated with reductions in pro-inflammatory cytokines including interleukin-1β, interleukin-8, and prostaglandin E2 in gingival crevicular fluid. These mechanisms are strain-specific and have not been established for all probiotic strains.
No. All clinical evidence for probiotics in periodontal health was obtained as adjunct therapy — added to professional cleaning and standard hygiene, not substituted for it. No published evidence supports probiotic use as a replacement for dental scaling or periodontal treatment. Probiotics may be a reasonable complement to a professionally supervised oral care routine, but they should not replace standard dental care. Consult a dentist or periodontist if you have active gum disease.
Bio-K+ does not make any claim that its products contribute to gum health or oral health. Bio-K+'s products — fermented drinkables and probiotic capsules — are formulated and clinically validated for gut health applications only. The strains studied in periodontal research, particularly L. reuteri DSM 17938 and ATCC PTA 5289, are distinct from Bio-K+'s proprietary strains and carry independent clinical evidence for their specific oral health applications.
Follow @biokplus and tag us to be mentioned
